BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37896899)

  • 1. HHV-6A Infection of Papillary Thyroid Cancer Cells Induces Several Effects Related to Cancer Progression.
    Mardente S; Romeo MA; Asquino A; Po A; Gilardini Montani MS; Cirone M
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis.
    Caselli E; D'Accolti M; Soffritti I; Zatelli MC; Rossi R; Degli Uberti E; Di Luca D
    Virol J; 2017 Jan; 14(1):3. PubMed ID: 28081700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells.
    Lima CR; Geraldo MV; Fuziwara CS; Kimura ET; Santos MF
    BMC Cancer; 2016 Feb; 16():108. PubMed ID: 26883911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells.
    Mardente S; Mari E; Consorti F; Di Gioia C; Negri R; Etna M; Zicari A; Antonaci A
    Oncol Rep; 2012 Dec; 28(6):2285-9. PubMed ID: 23023232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-124-3p inhibits tumourigenesis by targeting mitogen-activated protein kinase 4 in papillary thyroid carcinoma.
    Sun Y; Zhang L; Zhang S
    Cell Biochem Funct; 2020 Dec; 38(8):1017-1024. PubMed ID: 32495394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
    Geraldo MV; Nakaya HI; Kimura ET
    Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor.
    Feng K; Liu Y; Xu LJ; Zhao LF; Jia CW; Xu MY
    Biomed Pharmacother; 2018 Aug; 104():686-698. PubMed ID: 29803929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
    Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
    Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
    Fuziwara CS; Saito KC; Kimura ET
    Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
    [No Abstract]   [Full Text] [Related]  

  • 11. Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1α and microRNA-146a.
    Long M; Zhu Y; Chen Z; Lin S; Peng X; Luo D; Li H; Tan L
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32303750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.
    Yang Y; Xia S; Zhang L; Wang W; Chen L; Zhan W
    Cancer Biol Ther; 2020 Jun; 21(6):522-532. PubMed ID: 32151175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes increased angiogenesis in papillary thyroid cancer microenvironment.
    Wu F; Li F; Lin X; Xu F; Cui RR; Zhong JY; Zhu T; Shan SK; Liao XB; Yuan LQ; Mo ZH
    Endocr Relat Cancer; 2019 May; 26(5):525-538. PubMed ID: 30870812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncoding RNAs in Papillary Thyroid Cancer: Interaction with Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment (TME) and Regulators of Differentiation and Lymph Node Metastasis.
    Dadafarin S; Carnazza M; Islam HK; Moscatello A; Tiwari RK; Geliebter J
    Adv Exp Med Biol; 2021; 1350():145-155. PubMed ID: 34888848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of pro-inflammatory genes and down-regulation of SOCS-1 in human PTC and in hypoxic BCPAP cells.
    De Santis E; Di Vito M; Perrone GA; Mari E; Osti M; De Antoni E; Coppola L; Tafani M; Carpi A; Russo MA
    Biomed Pharmacother; 2013 Feb; 67(1):7-16. PubMed ID: 23089475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A human herpesvirus 6A-encoded microRNA: role in viral lytic replication.
    Nukui M; Mori Y; Murphy EA
    J Virol; 2015 Mar; 89(5):2615-27. PubMed ID: 25520507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
    Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
    Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle.
    Sun J; Shi R; Zhao S; Li X; Lu S; Bu H; Ma X; Su C
    J Exp Clin Cancer Res; 2017 Mar; 36(1):40. PubMed ID: 28270228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IRAK1, a Target of miR-146b, Reduces Cell Aggressiveness of Human Papillary Thyroid Carcinoma.
    Chou CK; Chi SY; Huang CH; Chou FF; Huang CC; Liu RT; Kang HY
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4357-4366. PubMed ID: 27533309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
    Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
    Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.